Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Income Statement
Earnings Waterfall
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Revenue
|
881.3m
CNY
|
Cost of Revenue
|
-47.2m
CNY
|
Gross Profit
|
834.1m
CNY
|
Operating Expenses
|
-506.1m
CNY
|
Operating Income
|
328m
CNY
|
Other Expenses
|
-11.1m
CNY
|
Net Income
|
316.9m
CNY
|
Income Statement
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
202
N/A
|
211
+4%
|
228
+8%
|
240
+5%
|
247
+3%
|
252
+2%
|
261
+3%
|
267
+2%
|
277
+4%
|
283
+2%
|
303
+7%
|
312
+3%
|
324
+4%
|
344
+6%
|
367
+7%
|
386
+5%
|
411
+7%
|
439
+7%
|
478
+9%
|
501
+5%
|
532
+6%
|
557
+5%
|
615
+11%
|
639
+4%
|
612
-4%
|
625
+2%
|
631
+1%
|
636
+1%
|
691
+9%
|
724
+5%
|
765
+6%
|
808
+6%
|
841
+4%
|
849
+1%
|
888
+5%
|
896
+1%
|
882
-2%
|
893
+1%
|
870
-3%
|
848
-2%
|
881
+4%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
Cost of Revenue |
(9)
|
(11)
|
(11)
|
(10)
|
(12)
|
(13)
|
(13)
|
(13)
|
(15)
|
(14)
|
(14)
|
(12)
|
(12)
|
(12)
|
(13)
|
(14)
|
(22)
|
(25)
|
(32)
|
(29)
|
(29)
|
(27)
|
(26)
|
(23)
|
(26)
|
(31)
|
(31)
|
(29)
|
(34)
|
(33)
|
(35)
|
(34)
|
(40)
|
(40)
|
(44)
|
(41)
|
(47)
|
(49)
|
(46)
|
(40)
|
(47)
|
|
Gross Profit |
194
N/A
|
201
+4%
|
217
+8%
|
230
+6%
|
235
+2%
|
239
+2%
|
247
+3%
|
254
+3%
|
263
+3%
|
269
+2%
|
290
+8%
|
301
+4%
|
312
+4%
|
331
+6%
|
355
+7%
|
372
+5%
|
390
+5%
|
414
+6%
|
446
+8%
|
472
+6%
|
503
+6%
|
529
+5%
|
589
+11%
|
617
+5%
|
586
-5%
|
594
+1%
|
600
+1%
|
608
+1%
|
657
+8%
|
691
+5%
|
730
+6%
|
773
+6%
|
801
+4%
|
809
+1%
|
844
+4%
|
855
+1%
|
834
-2%
|
844
+1%
|
823
-2%
|
808
-2%
|
834
+3%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(117)
|
(116)
|
(121)
|
(123)
|
(116)
|
(118)
|
(121)
|
(127)
|
(131)
|
(136)
|
(141)
|
(152)
|
(153)
|
(156)
|
(161)
|
(167)
|
(170)
|
(182)
|
(198)
|
(220)
|
(237)
|
(254)
|
(281)
|
(300)
|
(299)
|
(304)
|
(312)
|
(314)
|
(328)
|
(353)
|
(372)
|
(409)
|
(413)
|
(406)
|
(423)
|
(485)
|
(495)
|
(522)
|
(529)
|
(494)
|
(506)
|
|
Selling, General & Administrative |
(115)
|
(114)
|
(120)
|
(112)
|
(115)
|
(117)
|
(120)
|
(116)
|
(129)
|
(135)
|
(140)
|
(142)
|
(151)
|
(155)
|
(158)
|
(159)
|
(168)
|
(178)
|
(193)
|
(204)
|
(223)
|
(232)
|
(253)
|
(257)
|
(253)
|
(253)
|
(253)
|
(260)
|
(279)
|
(299)
|
(317)
|
(330)
|
(341)
|
(341)
|
(357)
|
(355)
|
(365)
|
(379)
|
(380)
|
(373)
|
(401)
|
|
Research & Development |
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(10)
|
0
|
0
|
0
|
(9)
|
0
|
0
|
(2)
|
(8)
|
0
|
0
|
(3)
|
(11)
|
(14)
|
(22)
|
(31)
|
(35)
|
(46)
|
(52)
|
(60)
|
(56)
|
(74)
|
(79)
|
(81)
|
(75)
|
(95)
|
(98)
|
(103)
|
(92)
|
(104)
|
(107)
|
(108)
|
(96)
|
(118)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(12)
|
0
|
0
|
0
|
(22)
|
0
|
0
|
0
|
(24)
|
0
|
0
|
0
|
(33)
|
0
|
|
Other Operating Expenses |
(2)
|
(2)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(1)
|
1
|
(0)
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
3
|
0
|
0
|
0
|
0
|
15
|
25
|
26
|
26
|
18
|
22
|
33
|
37
|
(14)
|
(27)
|
(37)
|
(41)
|
8
|
14
|
|
Operating Income |
77
N/A
|
85
+10%
|
97
+14%
|
107
+10%
|
119
+12%
|
121
+2%
|
126
+4%
|
127
+1%
|
132
+4%
|
133
+1%
|
148
+12%
|
148
0%
|
160
+8%
|
176
+10%
|
194
+10%
|
205
+6%
|
220
+7%
|
232
+6%
|
248
+7%
|
252
+2%
|
266
+5%
|
275
+3%
|
308
+12%
|
317
+3%
|
287
-9%
|
289
+1%
|
288
-1%
|
294
+2%
|
328
+12%
|
339
+3%
|
357
+6%
|
364
+2%
|
388
+6%
|
403
+4%
|
421
+5%
|
369
-12%
|
339
-8%
|
322
-5%
|
294
-9%
|
314
+7%
|
328
+4%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
1
|
2
|
3
|
6
|
7
|
8
|
8
|
7
|
7
|
7
|
7
|
8
|
8
|
9
|
10
|
12
|
13
|
15
|
17
|
19
|
22
|
24
|
26
|
27
|
26
|
26
|
28
|
27
|
28
|
29
|
27
|
29
|
30
|
30
|
30
|
27
|
27
|
27
|
26
|
31
|
30
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
(5)
|
(5)
|
(5)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
2
|
5
|
5
|
7
|
6
|
5
|
5
|
5
|
5
|
2
|
2
|
0
|
1
|
1
|
5
|
3
|
2
|
1
|
2
|
2
|
1
|
3
|
4
|
2
|
4
|
3
|
9
|
1
|
(0)
|
1
|
(7)
|
0
|
1
|
(0)
|
0
|
3
|
2
|
2
|
1
|
1
|
1
|
|
Pre-Tax Income |
80
N/A
|
92
+15%
|
105
+13%
|
119
+14%
|
132
+11%
|
134
+2%
|
139
+4%
|
139
0%
|
143
+3%
|
142
-1%
|
154
+8%
|
152
-1%
|
164
+8%
|
181
+11%
|
205
+13%
|
219
+7%
|
235
+7%
|
248
+6%
|
266
+7%
|
273
+3%
|
289
+6%
|
302
+5%
|
337
+12%
|
346
+2%
|
317
-8%
|
318
+0%
|
325
+2%
|
323
-1%
|
356
+10%
|
368
+4%
|
378
+2%
|
393
+4%
|
418
+6%
|
432
+3%
|
451
+4%
|
399
-11%
|
367
-8%
|
351
-5%
|
322
-8%
|
346
+8%
|
359
+4%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
(12)
|
(14)
|
(15)
|
(19)
|
(22)
|
(23)
|
(23)
|
(21)
|
(21)
|
(21)
|
(25)
|
(23)
|
(25)
|
(27)
|
(29)
|
(33)
|
(35)
|
(37)
|
(40)
|
(41)
|
(44)
|
(46)
|
(52)
|
(53)
|
(49)
|
(50)
|
(52)
|
(53)
|
(58)
|
(61)
|
(65)
|
(67)
|
(71)
|
(72)
|
(72)
|
(63)
|
(54)
|
(49)
|
(45)
|
(50)
|
(57)
|
|
Income from Continuing Operations |
68
|
78
|
90
|
100
|
110
|
112
|
116
|
118
|
122
|
121
|
129
|
129
|
139
|
154
|
175
|
186
|
200
|
211
|
227
|
232
|
245
|
257
|
286
|
293
|
267
|
268
|
273
|
270
|
297
|
308
|
313
|
326
|
348
|
360
|
379
|
336
|
314
|
301
|
277
|
296
|
302
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
6
|
6
|
7
|
8
|
9
|
10
|
11
|
11
|
12
|
12
|
11
|
12
|
13
|
14
|
15
|
15
|
15
|
14
|
|
Net Income (Common) |
68
N/A
|
78
+16%
|
90
+14%
|
100
+11%
|
111
+11%
|
112
+1%
|
116
+4%
|
118
+2%
|
122
+4%
|
121
-1%
|
129
+7%
|
129
N/A
|
139
+8%
|
154
+11%
|
175
+14%
|
186
+6%
|
200
+7%
|
211
+6%
|
227
+7%
|
233
+3%
|
247
+6%
|
259
+5%
|
290
+12%
|
298
+3%
|
274
-8%
|
275
+1%
|
281
+2%
|
278
-1%
|
308
+10%
|
319
+4%
|
324
+2%
|
338
+4%
|
359
+6%
|
372
+3%
|
391
+5%
|
349
-11%
|
328
-6%
|
316
-3%
|
292
-8%
|
310
+6%
|
317
+2%
|
|
EPS (Diluted) |
0.14
N/A
|
0.2
+43%
|
0.17
-15%
|
0.19
+12%
|
0.21
+11%
|
0.22
+5%
|
0.23
+5%
|
0.23
N/A
|
0.23
N/A
|
0.23
N/A
|
0.24
+4%
|
0.25
+4%
|
0.26
+4%
|
0.29
+12%
|
0.33
+14%
|
0.36
+9%
|
0.38
+6%
|
0.4
+5%
|
0.43
+7%
|
0.44
+2%
|
0.47
+7%
|
0.49
+4%
|
0.55
+12%
|
0.57
+4%
|
0.52
-9%
|
0.53
+2%
|
0.54
+2%
|
0.53
-2%
|
0.58
+9%
|
0.6
+3%
|
0.61
+2%
|
0.65
+7%
|
0.69
+6%
|
0.71
+3%
|
0.75
+6%
|
0.67
-11%
|
0.63
-6%
|
0.6
-5%
|
0.56
-7%
|
0.59
+5%
|
0.61
+3%
|